MEI Pharma Inc
For the period ended Jun 30, 2024. Filed Sep 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 19, 2024
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| For the Fiscal Year Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $17,778 | $(31,838) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Change in fair value of warrant liability | — | (1,603) |
| Share-based compensation | 2,278 | 3,589 |
| Issuance of warrants | — | 500 |
| Impairment of long-lived assets | 10,899 | — |
| Noncash lease expense | 2,433 | 1,429 |
| Depreciation expense | 383 | 386 |
| Loss on disposal of property and equipment | 32 | — |
| Changes in operating assets and liabilities: | ||
| Unbilled receivables | 85 | 9,959 |
| Prepaid expenses and other current assets | 4,534 | (2,920) |
| Accounts payable | (3,147) | (1,784) |
| Accrued liabilities | (7,274) | 1,641 |
| Deferred revenue | (64,862) | (30,582) |
| Operating lease liability | (13,612) | (1,261) |
| Net cash used in operating activities | (50,473) | (52,484) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (58,232) | (101,764) |
| Proceeds from maturity of short-term investments | 107,379 | 155,489 |
| Purchases of property and equipment | (7) | (35) |
| Net cash provided by investing activities | 49,140 | 53,690 |
| Cash flows from financing activities: | ||
| Payments of tax withholdings related to vesting of restricted stock units | — | (40) |
| Payment of cash dividend | (11,660) | — |
| Payment of financing costs | (208) | — |
| Net cash used in financing activities | (11,868) | (40) |
| Net (decrease) increase in cash and cash equivalents | (13,201) | 1,166 |
| Cash and cash equivalents at beginning of the year | 16,906 | 15,740 |
| Cash and cash equivalents at end of the year | $3,705 | $16,906 |
| Supplemental cash flow information: | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $— | $4,347 |
| Re-measurement of right-of-use asset and related lease liability upon lease modification | $(22) | $— |
| Re-measurement of right-of-use asset for direct costs associated with lease modification | $181 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.